Feedback-Amplified Drug Delivery of αPD-L1-Modified Lipoplatin for Chronological Synergy in NSCLC through PD-L1
Yi Cen1, Xin-Xuan Li1, Ying Chen1
1Fifth Affiliated Hospital, Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, P. R. China.
Abstract:
The limited efficacy of PD-L1 blockade in non-small cell lung cancer (NSCLC) patients with low PD-L1 expression necessitates the optimization of therapeutic strategies. In this study, we found that PD-L1 expression levels correlate with survival outcomes in αPD-L1-treated NSCLC patients and cisplatin significantly upregulates PD-L1 expression. Building on these findings, PD-L1 antibody-conjugated liposomal cisplatin (αPD-L1@Lipoplatin) is fabricated to integrate chemotherapy-induced PD-L1 upregulation with feedback-enhanced drug delivery and targeted immune checkpoint blockade to enhance NSCLC immunotherapy. Interestingly, the selective targeting ability of αPD-L1@Lipoplatin further upregulates PD-L1 expression, creating a positive feedback loop that continually increases the density of targeting sites and improves drug delivery efficiency. In parallel, αPD-L1@Lipoplatin enhances cytotoxic CD8+ T-cell infiltration, suppresses immunosuppressive regulatory T cells, and increases intratumoral levels of interferon-γ (IFN-γ) and granzyme B, contributing to the chronological synergy between chemotherapy and immunotherapy, thereby boosting the αPD-L1 response and NSCLC inhibition. Importantly, αPD-L1@Lipoplatin effectively suppresses tumor growth without causing significant hepatorenal toxicity, maintaining stable body weight and showing no histopathological abnormalities in major organs. This feedback-amplified drug delivery system offers a promising strategy to enhance drug delivery efficiency and αPD-L1 responsiveness, holding great potential for improving NSCLC immunotherapy.
Insights
This study developed a novel drug delivery system, αPD-L1@Lipoplatin, to improve immunotherapy for non-small cell lung cancer (NSCLC). This system enhances drug delivery and boosts the immune response against tumors, showing promising results in preclinical models.
Area of Science:
- Immunology
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Limited efficacy of PD-L1 blockade in non-small cell lung cancer (NSCLC) with low PD-L1 expression requires optimized therapeutic strategies.
- PD-L1 expression correlates with survival in NSCLC patients treated with PD-L1 blockade.
- Cisplatin chemotherapy significantly upregulates PD-L1 expression.
Purpose of the Study:
- To develop a novel drug delivery system, αPD-L1@Lipoplatin, integrating chemotherapy and immunotherapy for enhanced NSCLC treatment.
- To investigate the feedback-enhanced drug delivery and immune checkpoint blockade capabilities of αPD-L1@Lipoplatin.
- To evaluate the therapeutic efficacy and safety of αPD-L1@Lipoplatin in NSCLC models.
Main Methods:
- Fabrication of PD-L1 antibody-conjugated liposomal cisplatin (αPD-L1@Lipoplatin).
- Investigation of the positive feedback loop mechanism for drug delivery enhancement.
- Assessment of immune cell infiltration (CD8+ T cells, regulatory T cells) and cytokine levels (IFN-γ, granzyme B).
- Evaluation of tumor growth inhibition and systemic toxicity (hepatorenal, body weight, organ histopathology).
Main Results:
- αPD-L1@Lipoplatin demonstrated selective targeting, upregulating PD-L1 expression via a positive feedback loop to improve drug delivery efficiency.
- The system enhanced cytotoxic CD8+ T-cell infiltration, suppressed regulatory T cells, and increased intratumoral IFN-γ and granzyme B.
- Chronological synergy between chemotherapy and immunotherapy boosted the anti-PD-L1 response and NSCLC inhibition.
- αPD-L1@Lipoplatin effectively suppressed tumor growth with no significant hepatorenal toxicity or adverse effects on major organs.
Conclusions:
- The feedback-amplified drug delivery system, αPD-L1@Lipoplatin, offers a promising strategy to enhance drug delivery efficiency and PD-L1 responsiveness in NSCLC.
- This integrated approach holds significant potential for improving immunotherapy outcomes in non-small cell lung cancer.
- αPD-L1@Lipoplatin presents a viable therapeutic option with a favorable safety profile for NSCLC treatment.
